Biologic Manufacturers Should Expect Antitrust Scrutiny

By James Kovacs and Ankur Kapoor (April 17, 2019, 4:16 PM EDT) -- Democrats and Republicans agree on few issues, but one of them is that something must be done about the high cost of medical drugs in the United States. While government antitrust enforcers have paid much attention over the last two decades to competition from generic pharmaceuticals, there has recently been antitrust scrutiny by private plaintiffs on competition among biologics and their interchangeable biosimilars....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!